Condition

Urothelial Carcinoma Recurrent clinical trials and research

• 7Clinical trials
• 1New in 30 days
• 4Countries

Newest Urothelial Carcinoma Recurrent clinical trials

All recruiting trials (7)

• BL-M07D1: T-bren vs standard platinum chemo for HER2-expressing metastatic urothelial cancer after anti-PD-(L)1 therapy

  This trial tests whether T-bren can help people with HER2-expressing metastatic urothelial cancer who progressed after anti-PD-(L)1 therapy, compared with standard platinum-based chemotherapy.

  Recruiting at 2 sites Phase 3 SystImmune Inc. · Macon, Georgia and 1 other locations · NCT07869836

• Intravesical UGN-501 for Recurrent NMIBC (Phase 1, dose-escalation)

  This study tests whether UGN-501 can be safely given into the bladder to treat adults with recurrent non-muscle invasive bladder cancer.

  Recruiting at 6 sites Phase 1 UroGen Pharma Ltd. · Queen Creek, Arizona and 14 other locations · NCT07725796

• Trastuzumab Rezetecan with or without Adebrelimab for HER2-expressing advanced urothelial cancer

  This study will test whether Trastuzumab Rezetecan alone or combined with the immunotherapy Adebrelimab helps people with HER2-expressing locally advanced or metastatic urothelial cancer.

  Recruiting at 3 sites Phase 2 Sun Yat-sen University · Guangzhou, Guangdong and 5 other locations · NCT07241793

• Combination treatment for advanced urothelial carcinoma

  This study is testing a new combination of a drug called AM80 with standard chemotherapy and immunotherapy to see if it helps people with advanced bladder cancer feel better and live longer.

  Recruiting Phase 2 Nagoya University · Nagoya, Aichi-ken · NCT06983210

• Comparing two treatments for advanced urothelial carcinoma

  This study is testing if a combination of two treatments can help people with advanced bladder cancer do better than using just one of the treatments alone.

  Recruiting at 2 sites Phase 2 Mabwell (Shanghai) Bioscience Co., Ltd. · Changsha, Hunan and 1 other locations · NCT06823427

• Registry of patients with upper tract urothelial cancer treated with Jelmyto

  This study is looking at how well Jelmyto works for people with upper tract urothelial cancer by tracking their experiences and outcomes over time.

  Recruiting at 22 sites UroGen Pharma Ltd. · Santa Monica, California and 21 other locations · NCT05874921

• Evaluating Verity-BCG for treating high-risk non-muscle invasive bladder cancer

  This study is testing a new treatment called Verity-BCG to see if it can help people with high-risk bladder cancer stay cancer-free for longer compared to the standard treatment they usually receive.

  Recruiting at 4 sites Phase 3 Verity Pharmaceuticals Inc. · Vancouver, British Columbia and 5 other locations · NCT05037279

Related topics

Quick answers

How many Urothelial Carcinoma Recurrent clinical trials are recruiting right now?

7, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 4 countries. The most sites are in United States (3 trials), China (2 trials), Japan (1 trial), Canada (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3, Phase 3: 2, Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →